{"id":"carboplatin-cb","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Myelosuppression"},{"rate":"20-40%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Thrombocytopenia"},{"rate":"10-30%","effect":"Anemia"},{"rate":"50-70%","effect":"Nausea and vomiting"},{"rate":"20-40%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Anorexia"},{"rate":"50-70%","effect":"Hair loss"},{"rate":"10-30%","effect":"Neuropathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This mechanism is achieved through the formation of platinum-DNA adducts, which cause DNA damage and trigger apoptosis in rapidly dividing cancer cells. The platinum atom in carboplatin binds to DNA, leading to the formation of cross-links and other DNA damage, which ultimately results in cell death.","oneSentence":"Carboplatin works by forming platinum-DNA adducts, which interfere with DNA replication and transcription, ultimately leading to cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:05:00.070Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ovarian cancer"},{"name":"Non-small cell lung cancer"},{"name":"Breast cancer"},{"name":"Testicular cancer"},{"name":"Urothelial cancer"}]},"trialDetails":[{"nctId":"NCT03126916","phase":"PHASE3","title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-14","conditions":"Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":750},{"nctId":"NCT06817525","phase":"PHASE2","title":"Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-11-06","conditions":"Triple-negative Breast Cancer","enrollment":64},{"nctId":"NCT07001618","phase":"PHASE2","title":"Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-09","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer)","enrollment":162},{"nctId":"NCT06435104","phase":"PHASE2","title":"Aromatherapy in the Treatment of Early Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-07","conditions":"Early Breast Cancer","enrollment":30},{"nctId":"NCT06371807","phase":"PHASE2","title":"Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab","status":"NOT_YET_RECRUITING","sponsor":"Fundacao Champalimaud","startDate":"2024-07","conditions":"Early Breast Cancer, Triple Negative Breast Cancer","enrollment":20},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT05159193","phase":"PHASE3","title":"Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-12-20","conditions":"Breast Cancer","enrollment":372},{"nctId":"NCT00432172","phase":"PHASE2","title":"Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2007-04-24","conditions":"Breast Cancer","enrollment":189},{"nctId":"NCT02622074","phase":"PHASE1","title":"Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-01-27","conditions":"Triple Negative Breast Neoplasms","enrollment":60},{"nctId":"NCT02125344","phase":"PHASE3","title":"A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2014-12","conditions":"Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III, Mucinous Breast Cancer Stage II","enrollment":961},{"nctId":"NCT00499109","phase":"PHASE3","title":"Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2007-05","conditions":"Non-Small Cell Lung Cancer","enrollment":275}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":26,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["kabo"],"phase":"phase_3","status":"active","brandName":"carboplatin (Cb)","genericName":"carboplatin (Cb)","companyName":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","companyId":"sun-yat-sen-memorial-hospital-of-sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Carboplatin is a small molecule DNA inhibitor used in the treatment of various conditions, including Triple-negative Breast Cancer, Accelerated Phase Chronic Myelogenous Leukemia, and Hodgkin Lymphoma. It is often administered in combination with other treatments, such as Nab-P and PD1 inhibitors, as part of neoadjuvant therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}